European Commission Approval for biosimilar epoetin alfa
The European Commission's decision to grant this approval followed a positive opinion in June from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP), which reviews medicines scientifically for the Commission.
more info ....

Performance in first half of 2007
Novartis delivers strong performance in first half of 2007
more info ....

Strong performance with record full-year results in 2006
Novartis strategic healthcare portfolio drives sustained strong performance with record full-year results in 2006
more info ....

Sandoz on the move
To introduce our new company name to the public, Sandoz is advertising on trams in Bratislava. Trams are a powerful medium for promoting our message, reaching mass audiences in the heart of the city.
more info ....

Novartis generates strong sales and earnings growth in the first six months of 2006, growing faster than the world pharmaceuticals market
Novartis generates strong sales and earnings growth in the first six months of 2006, growing faster than the world pharmaceuticals market
more info ....

Thousands of Novartis associates worldwide participated in the 10th Community Partnership Day
All over the world, Novartis associates have taken part in Community Partnership Day (CPD), supporting their local communities through a wide range of voluntary activities.
more info ....

Sandoz Receives European Commission Marketing Authorization for Omnitrope
HOLZKIRCHEN, Germany – Sandoz announced today that the European Commission has granted marketing authorization for the company’s recombinant human growth hormone Omnitrope®.
more info ....

Sandoz Welcomes CHMP Positive Opinion on Omnitrope
“The positive CHMP opinion for Omnitrope is an important step on the way to make this medicine available for patients who need it,” said Dr. Andreas Rummelt, CEO Sandoz. “Omnitrope will contribute to cost savings in the Health Care systems and we are confident that the European Commission will now grant marketing authorization.”
more info ....

The celebration of "A Healthy decision" - Sandoz gala evening at the theater Nova Scena
On Feb 9th a celebration gala was held at the theater Nova Scena to commemorate Sandoz, along with its former Lek d.d. and Biochemie GmbH, re-entering the Slovak Market. The gala was a spectacular finale of an ongoing intensive re-branding campaign, marketing the brand name “Sandoz” to both the public and Healthcare professionals.
more info ....

Novartis delivers strong performance with record results in 2005
Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said, "It gives me great pleasure to present once again a strong performance and record results in 2005...
more info ....

SANDOZ – a world leader in generic drug market now in Slovakia
In 2002, following the acquisition of Lek d.d, Sandoz became one of the leaders of generic pharmaceutical producers in Central and Eastern Europe. Now in 2006, Sandoz, along with it’s former Biochemie GmbH, enters the Slovak market under the common brand name Sandoz.
more info ....

The return of the Future. Sandoz comes back to Slovakia
Beginning of 2006, Sandoz - one of the world leaders in generic drugs, will be also present in Slovakia. The usage of the global Sandoz brand company follows their acquisition of the major central European producer Lek in 2002.
more info ....

Results III. Q 2005
Novartis delivers strong growth in first nine months of 2005, on track to achieve full-year sales and earnings objectives
more info ....

Novartis announces final results of Eon Labs tender offer
Novartis announced today the final results of the cash tender offer by Zodnas Acquisition Corp., an indirect wholly owned subsidiary of Novartis AG, for the outstanding public shares of Eon Labs, Inc.
more info ....

Novartis announces completion of Hexal AG acquisition, integrates company with Sandoz
Novartis announced today the completion of its acquisition of the generic pharmaceutical company Hexal AG in Germany on June 6. The acquisition was approved by the European Commission in late May.
more info ....

Novartis receives European Commission approval to acquire Hexal AG, further step toward creating world leader in Generics
Novartis announced today that it has received approval from the European Commission to acquire the privately-held generic pharmaceutical company Hexal AG of Germany. The acquisition is expected to be completed in early June.
more info ....

Novartis Community Partnership Day 2005 High Tatras
Community Partnership Day is a tradition that takes place in every country where Novartis or any of its sister companies is present, where employees give of their time to improve the healthcare, social or environmental aspects of their communities.
more info ....

New Sandoz Global Headquarters site
Novartis provides progress update on plants in integrate Hexal and Eon Labs with Sandoz.
more info ....

The first-quarter 2005 results
Novartis continues to outpace the market, delivering strong first quarter 2005 sales and earnings growth
more info ....

Creating a fast-growing world leader in generics
Novartis announced today the strategic acquisition of two leading generic drug companies that will be integrated into its Sandoz division, creating the world leader in the generic drug industry.
more info ....

Boosting innovation for a competitive Europe
Sandoz and the SME Union of the European People's Party hosted a symposium in Brussels.
more info ....

GENAS Gears up for change in Slovakia
Slovakia's December amendment to its Medicines Act, requiring patients to demand generics rather than accept them as a matter of course, is just one of the many chalenges facing Chrisitan Wieser, the new president of GENAS, the Slovak generic industry association.
more info ....

GENAS – new executive committee elected
The recently constituted new executive committee of the Slovak Generic association GENAS elected Christian Wieser for their new president. He will be supported by two other members of the presidium, Mrs. Alzbeta Krempová (Hoechst Biotika) and Mr. Rudolf Husár (Richter Gedeon). Wieser follows in this position the previous president Alexander Černák, CEO Zentiva Slovakia.
more info ....

Ketonal 2,5% gel available in Slovakian pharmacies
Since 11/01/2004 Ketonal 2.5% gel is available for patients at various pharmacies across Slovakia. Ketonal 2.5% gel's quick absorption and deep tissue penetration provides early relief for painful conditions.
more info ....

Sandoz launches Cholesterol lowering Drug in European Union based on Lek Expertise
Sandoz, the generic business of Novartis, launched a generic version of pravastatin (cholesterol lowering drug) today in the United Kingdom, Germany, the Netherlands and Denmark. The product, which is a result of Lek knowledge, will be marketed through Sandoz entities on the respective markets. The launch of pravastatin is a successful alliance of Lek development, registrations, production and other key knowledge with Sandoz global sales network.
more info ....

Sandoz to strengthen Danish market position and Nordic operations with acquisition of Astra Zeneca’s generics subsidiary in Denmark
Acquisition of Durascan makes Sandoz number two player in local generics market and provides operational hub for entire Nordic region.
more info ....

Sandoz makes major entry into generic injectables field with acquisition of fastgrowing Sabex Holdings Ltd. of Canada
Sandoz, a Novartis company, today announced plans to acquire Sabex Holdings Ltd. in a USD 565 million cash transaction that will provide strong growth opportunities in injectable generics and new entry into the Canadian generics sector.
more info ....

Lek confirms commitment to Romania with important investment in Targu Mures
Lek, a new Sandoz company, today inaugurated a new pharmaceutical plant in Targu Mures, Romania, 340 km from Bucharest. Focusing on macrolide antibiotics, the 4,550-square-meter complex will include an administration building, laboratories, production lines and storage center. Out of total investment of 30 million USD in Romania, the Targu-Mures macrolide production competence center investment is 12 million USD. The facility will provide products for the growing needs of the entire European market and will support the continued growth of Sandoz. The plant was officially inaugurated by Slovenian Prime Minister Anton Rop and Romanian Minister of Health Dr. Ovidiu Brinzan.
more info ....

Sandoz: Celebrating the successful return of a trusted brand
One year ago today, on May 21, 2003, the trusted Sandoz name returned to the market place as the unifying brand for the 14 individual companies that comprise Novartis’ generics business. Sandoz is once again recognized as leading brand in the medicine business, despite having faded from sight after the 1996 merger of Sandoz and Ciba-Geigy that created Novartis. May marks the first anniversary of the consolidation of the Novartis generics business under the Sandoz name. Sandoz is the world’s second biggest generic business after a record year in 2003. Customers and partners react positively to the reintroduction of a well-known brand.
more info ....

Sandoz strengthens global production network with three new facilities
New plants to open in Poland, India and Romania in May. Sandoz, the world’s second largest supplier of generic medicines, is expanding its global production network with the opening of three new plants this month in Poland, India and Romania. The USD 80 million total investment will boost production capacity by three billion tablets and capsules, while creating approximately 500 jobs.
more info ....

Novartis confirms commitment to new markets of the European Union with major investment in Poland
Signalling its continued commitment to the emerging economies of the recently expanded European Union, Novartis AG today announced a EUR 70 million overall investment in a new generics production and logistics facility Stryków, Poland.
more info ....

Novartis Community Partnership Day, 27 April, 2004 in Slovakia
Every year the Novartis Community Partnership Day unites a few thousand Novartis employees all around the world in the common cause of helping their local communities. Volunteers give their most precious resource - their time - to make their communities better places to live in.
more info ....